Found 5 matching trials
Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL PHASE2 The investigators propose a randomized phase 2 study evaluating 90Y-epratuz...
Show More Location
CHU de Clermont-Ferrand
Learn More & Join Trial
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL PHASE1 The goal of this study is to evaluate a new approach to immunotherapy in NH...
Show More Location
Helen F. Graham Cancer Center
Learn More & Join Trial
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia PHASE1 Determination of the maximum tolerated dose (MTD) of fractionated RIT with ...
Show More Location
Multiple Locations
Learn More & Join Trial
Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma PHASE2 Phase II, multi-centric, open-label, study.
Disseminated diffuse large B-c...
Show More Learn More & Join Trial
Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ PHASE1 The purpose of this study is to determine whether fractionated RIT with Epr...
Show More Learn More & Join Trial